All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The primary results of the phase II RADIUS study (NCT01883362) were reported at the 60th American Society of Hematology Annual Meeting & Exposition by Richard Thomas T. Maziarz from OR Health Sciences University, Portland, US. The phase II, randomized, exploratory RADIUS study is assessing whether the addition of midostaurin, a multi-targeted tyrosine kinase inhibitor, to standard of care (SOC) after allogeneic stem cell transplantation (alloSCT) can reduce the risk of relapse in patients with fms-like tyrosine kinase 3-internal tandem duplication positive (FLT3-ITD+) acute myeloid leukemia (AML).
In this study, 60 patients with FLT3-ITD+ AML who underwent myeloablative alloSCT in first complete remission (CR1) were randomized to receive SOC with (n = 30; median age = 48 years) or without (n = 30; median age = 56 years) midostaurin (50 mg twice daily, continuous 28 day cycles). Treatment began 28–60 days after alloSCT. The median duration of exposure in the midostaurin arm was 10.5 months (range: 1.2–11.5 months) and the median dose intensity was 93 mg/day (range, 25–100 mg/day).
The primary objective of the study was relapse-free survival (RFS) at 18 months post-alloSCT. Key secondary objectives include safety and RFS at 24 months post-alloSCT.
The speaker stated that maintenance therapy with midostaurin may contribute to a 54% relative reduction in the risk of relapse versus SOC alone. In addition, midostaurin was well tolerated and did not increase the rates or severity of GvHD.
In an interview with the AGP, Richard Maziarz concluded that the midostaurin monotherapy can be safely administered in the post-transplant setting and may improve outcomes in patients who undergo alloSCT in CR1.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox